37866-45-8

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE is used as a chemical intermediate for the preparation of istaroxime analogs, which are important in the development of pharmaceuticals that can potentially improve cardiovascular health and treat related conditions.
Used in Chemical Synthesis:
As a white solid, 2-AMINOOXYETHYLAMINE DIHYDROCHLORIDE is also used in chemical synthesis processes, where it serves as a key component in the production of various compounds and materials with specific applications in different fields.

InChI:InChI=1/C2H8N2O.2ClH/c3-1-2-5-4;;/h1-4H2;2*1H

Upstream product

• 222960-38-5 N-(2-aminoethoxy)benzamide 
• 1259519-97-5 C₁₈H₁₆N₂O₄ 

Downstream Products

• 66882-97-1 1-(4-Chloro-phenyl)-7-(1-oxo-1λ⁴-thiomorpholin-4-yl)-heptan-1-one O-(2-amino-ethyl)-oxime 
• 66953-87-5 1-(4-Chloro-phenyl)-7-(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)-heptan-1-one O-(2-amino-ethyl)-oxime 
• 76852-19-2 1-(4-Chloro-phenyl)-4-morpholin-4-yl-butan-1-one O-(2-amino-ethyl)-oxime 
• 76852-11-4 1-(4-Chloro-phenyl)-3-dimethylamino-propan-1-one O-(2-amino-ethyl)-oxime 
• 76852-58-9 1-(4-Chloro-phenyl)-9-dimethylamino-nonan-1-one O-(2-amino-ethyl)-oxime 
• 76852-31-8 1-(4-Chloro-phenyl)-7-diethylamino-heptan-1-one O-(2-amino-ethyl)-oxime 

Relevant academic research and scientific papers

Novel approach to the synthesis of istaroxime

Istaroxime 1, a novel cardiotonic agent with high efficiency and low toxicity was synthesized from dehydroepiandrosterone 2 using a novel approach that included epoxidation, ring-opening, substitution, and oximation. The new protocol without gas protection was milder than the reported approaches. The overall yield of the method was 24.1%.

Novel synthesis method of Istaroxime

The invention belongs to the field of pharmaceutical chemistry, and discloses a novel synthesis method of Istaroxime. The method comprises the following steps: by using dehydrogenated epiandrosterone as an initial raw material, carrying out epoxidation, ring opening, reduction, oxidation and other reactions to prepare an intermediate M-06; by using ethyl benzoate as an initial raw material, reacting the ethyl benzoate with hydroxylamine hydrochloride to obtain phenyl hydroximic acid, carrying out hydrochlorination and chlorination by using ethanolamine as a raw material to obtain dichloroacetate, and carrying out substitution, hydrolysis and other reactions on the dichloroacetate and the phenyl hydroximic acid to obtain an intermediate M-11; and finally, reacting the M-06 with the M-11 to obtain the end product Istaroxime. According to the method, in the intermediate M-06 synthesis process, the polarity of all the intermediates has great differences from that of the impurities and reaction reagents; and in the intermediate 11 synthesis process, the active spots capable of participating in the chemical reaction in the reaction substrate are simple. Therefore, the method can achieve the requirements without carrying out column chromatography purification, thereby simplifying the synthesis after-treatment process.

MACROCYCLIC LACTONE DERIVATIVES AND USES THEREOF

The present invention provides compounds represented by Formula 1: wherein, R' is as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. The invention also relates to processes for the preparation of the compounds of Formula and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful for the treatment of inflammatory disorders and/or viral infections. The compounds and the pharmaceutical compositions of the present invention are also useful for the treatment of cancer.

COMPOUNDS AND METHODS FOR TREATING NEOPLASIA

The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.

17β-O-aminoalkyloximes of 5β-androstane-3β, 14β-diol with digitalis- like activity: Synthesis, cardiotonic activity, structure-activity relationships, and molecular modeling of the Na+,K+-ATPase receptor

A series of digitalis-like compounds with a 17-aminoalkoxyiminoalkyl or -alkenyl substituent was synthesized and evaluated for inhibition of Na+,K+-ATPase and for inotropic activity. The highest inhibition was found with compounds having the substituent in configuration 17β and the amino group at a distance of 6 or 7 bonds from C(17) of the digitoxigenin skeleton. The presence of the oxime function strengthens the interaction with the receptor, more if α,β-unsaturated, thus mimicking the electronic situation of the unsaturated lactone in natural digitalis compounds. The most active compounds showed Na+,K+-ATPase inhibitory potencies (IC50) 17-25 times higher than the standards digitoxigenin and digoxin and 3-11 times higher inotropic potencies (EC50) in isolated guinea pig left atria. These features are supported by a molecular model suggesting the possible interactions of the groups described above with particular amino acid residues in the H1-H2 domains of Na+,K+-ATPase. Some interactions are the classical ones already described in the literature; a new, very strong interaction of the basic group with the Cys138 was found and adds new possibilities to design compounds interacting with this region of the receptor. The most interesting compounds were also studied in vivo in the anesthetized guinea pig for evaluating their inotropic effect versus the lethal dose. Compounds 9 and 12 showed a slightly higher safety ratio than digoxin and deserve further evaluation.

Heteroatom-bearing ligands and metal complexes thereof

Novel compounds containing a heteroatom-bearing bridge and novel complexes of these compounds with metals. The novel compounds and complexes are useful in diagnostic and therapeutic methods.

AN IMPROVED SYNTHETIC ROUTE TO AMONOXYPROPYLAMINE (APA) AND RELATED HOMOLOGS

Aminoxypropylamine (APA) has been found to be a potent inhibitor of several enzymatic pathways involved in the biosynthesis of the naturally occuring polyamines putrescine, spermidine, and spermine.This report describes a convenient, three-step synthesis of APA, as well as its ethyl and butyl homologs, utilizing starting materials and intermediates useful in the preparation of other related aminoxyalkylamines.